New option for management of HIV-1 infection in treatment-naive patients: once-daily, fixed-dose combination of rilpivirine-emtricitabine-tenofovir

Nimish Patel1, Christopher D Miller1,21Albany College of Pharmacy and Health Sciences, 2Albany Medical Center Division of HIV Medicine, Albany, NYAbstract: Fixed-dose combination tablets have become an important therapy option for patients infected with the human immunodeficiency virus. Fixed-dose c...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Patel N, Miller CD
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2012
Materias:	Immunologic diseases. Allergy RC581-607
Acceso en línea:	https://doaj.org/article/880771383ffe451aa178a5f7078c71d8
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:880771383ffe451aa178a5f7078c71d8
record_format	dspace
spelling	oai:doaj.org-article:880771383ffe451aa178a5f7078c71d82021-12-02T02:30:24ZNew option for management of HIV-1 infection in treatment-naive patients: once-daily, fixed-dose combination of rilpivirine-emtricitabine-tenofovir1179-1373https://doaj.org/article/880771383ffe451aa178a5f7078c71d82012-04-01T00:00:00Zhttp://www.dovepress.com/new-option-for-management-of-hiv-1-infection-in-treatment-naive-patien-a9780https://doaj.org/toc/1179-1373Nimish Patel1, Christopher D Miller1,21Albany College of Pharmacy and Health Sciences, 2Albany Medical Center Division of HIV Medicine, Albany, NYAbstract: Fixed-dose combination tablets have become an important therapy option for patients infected with the human immunodeficiency virus. Fixed-dose combination rilpivirine-tenofovir-emtricitabine is a recently approved therapy option that has been extensively studied within the treatment-na&iuml;ve population. When compared with efavirenz-based therapy, improved tolerability with rilpivirine-based therapy was balanced by higher rates of virologic failure to provide similar overall efficacy rates within the intention-to-treat analysis. As a result, providers will need to balance the potential for improved tolerability with fixed-dose combination rilpivirine-tenofovir-emtricitabine against a higher potential for virologic failure, particularly among patients with baseline viral loads above 100,000 copies/mL. Current treatment guidelines have recommended that fixed-dose combination rilpivirine-tenofovir-emtricitabine be an alternative therapy option for treatment-na&iuml;ve patients and advise caution in those patients with high viral loads at baseline. Similar to other non-nucleoside reverse transcriptase inhibitor-based regimens, there are a number of drug interaction concerns with fixed-dose combination rilpivirine-tenofovir-emtricitabine that will necessitate monitoring and, in some cases, appropriate management. Additionally, the emergence of drug resistance to fixed-dose combination rilpivirine-tenofovir-emtricitabine has been well documented in clinical studies and close attention will be necessary in order to protect current and future therapy options. Overall, fixed-dose combination rilpivirine-tenofovir-emtricitabine is poised to provide an important therapy option for patients when appropriately applied.Keywords: rilpivirine, human immunodeficiency virus, antiretroviral, tenofovir, emtricitabinePatel NMiller CD,Dove Medical PressarticleImmunologic diseases. AllergyRC581-607ENHIV/AIDS: Research and Palliative Care, Vol 2012, Iss default, Pp 61-71 (2012)
institution	DOAJ
collection	DOAJ
language	EN
topic	Immunologic diseases. Allergy RC581-607
spellingShingle	Immunologic diseases. Allergy RC581-607 Patel N Miller CD, New option for management of HIV-1 infection in treatment-naive patients: once-daily, fixed-dose combination of rilpivirine-emtricitabine-tenofovir
description	Nimish Patel1, Christopher D Miller1,21Albany College of Pharmacy and Health Sciences, 2Albany Medical Center Division of HIV Medicine, Albany, NYAbstract: Fixed-dose combination tablets have become an important therapy option for patients infected with the human immunodeficiency virus. Fixed-dose combination rilpivirine-tenofovir-emtricitabine is a recently approved therapy option that has been extensively studied within the treatment-na&iuml;ve population. When compared with efavirenz-based therapy, improved tolerability with rilpivirine-based therapy was balanced by higher rates of virologic failure to provide similar overall efficacy rates within the intention-to-treat analysis. As a result, providers will need to balance the potential for improved tolerability with fixed-dose combination rilpivirine-tenofovir-emtricitabine against a higher potential for virologic failure, particularly among patients with baseline viral loads above 100,000 copies/mL. Current treatment guidelines have recommended that fixed-dose combination rilpivirine-tenofovir-emtricitabine be an alternative therapy option for treatment-na&iuml;ve patients and advise caution in those patients with high viral loads at baseline. Similar to other non-nucleoside reverse transcriptase inhibitor-based regimens, there are a number of drug interaction concerns with fixed-dose combination rilpivirine-tenofovir-emtricitabine that will necessitate monitoring and, in some cases, appropriate management. Additionally, the emergence of drug resistance to fixed-dose combination rilpivirine-tenofovir-emtricitabine has been well documented in clinical studies and close attention will be necessary in order to protect current and future therapy options. Overall, fixed-dose combination rilpivirine-tenofovir-emtricitabine is poised to provide an important therapy option for patients when appropriately applied.Keywords: rilpivirine, human immunodeficiency virus, antiretroviral, tenofovir, emtricitabine
format	article
author	Patel N Miller CD,
author_facet	Patel N Miller CD,
author_sort	Patel N
title	New option for management of HIV-1 infection in treatment-naive patients: once-daily, fixed-dose combination of rilpivirine-emtricitabine-tenofovir
title_short	New option for management of HIV-1 infection in treatment-naive patients: once-daily, fixed-dose combination of rilpivirine-emtricitabine-tenofovir
title_full	New option for management of HIV-1 infection in treatment-naive patients: once-daily, fixed-dose combination of rilpivirine-emtricitabine-tenofovir
title_fullStr	New option for management of HIV-1 infection in treatment-naive patients: once-daily, fixed-dose combination of rilpivirine-emtricitabine-tenofovir
title_full_unstemmed	New option for management of HIV-1 infection in treatment-naive patients: once-daily, fixed-dose combination of rilpivirine-emtricitabine-tenofovir
title_sort	new option for management of hiv-1 infection in treatment-naive patients: once-daily, fixed-dose combination of rilpivirine-emtricitabine-tenofovir
publisher	Dove Medical Press
publishDate	2012
url	https://doaj.org/article/880771383ffe451aa178a5f7078c71d8
work_keys_str_mv	AT pateln newoptionformanagementofhiv1infectionintreatmentnaivepatientsoncedailyfixeddosecombinationofrilpivirineemtricitabinetenofovir AT millercd newoptionformanagementofhiv1infectionintreatmentnaivepatientsoncedailyfixeddosecombinationofrilpivirineemtricitabinetenofovir
_version_	1718402420399144960

New option for management of HIV-1 infection in treatment-naive patients: once-daily, fixed-dose combination of rilpivirine-emtricitabine-tenofovir

Ejemplares similares